Previous 10 | Next 10 |
HOUSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that t...
2023-06-09 14:37:00 ET Gainers: Blue Apron Holdings ( APRN ) +65% . Sientra ( SIEN ) +50% . ContraFect ( CFRX ) +43% . Global Indemnity ( GBLI ) +23% . Disc Medicine Opco ( IRON ) +21% . Olema Pharmaceuticals ( OLMA ) +...
Marker Therapeutics, Inc. (NASDAQ: MRKR) is one of today's top gainers. The company's shares are currently up 13.94% on the day to $2.37. Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapie...
2023-06-01 08:30:01 ET Okta OKTA -19% after Q1earning release . Lexicon Pharmaceuticals ( LXRX ) -18% announces pricing of $125 Million public offering and concurrent private placement. C3.ai AI -17% after Q4 earning release . Victoria's Secret &...
2023-06-01 06:00:00 ET 3 Tips for Using Fundamental Analysis to Trade Penny Stocks Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer significan...
2023-05-31 10:05:20 ET Gainers: Marker Therapeutics ( MRKR ) +34% . Nano-X Imaging ( NNOX ) +13% . Zai Lab ( ZLAB ) +9% . Invivyd ( IVVD ) +8% . Corbus Pharmaceuticals ( CRBP ) +7% . Losers: Belite Bio ( BLTE ) ...
HOUSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced pre-cli...
2023-05-08 08:49:36 ET Clinical-stage immuno-oncology company, Marker Therapeutics ( NASDAQ: MRKR ) appoints of Monic Stuart, M.D., as its new Chief Medical Officer. Dr. Stuart brings more than 20 years of experience as a clinician-scientist and drug develop...
HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the app...
2023-05-01 12:10:17 ET If you’re looking for some of the most active penny stocks today, it doesn’t hurt to pay attention to trends. I’m not talking about what’s going on in tech or the latest energy stocks to watch. I’m referring to more micro trends. Thi...
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...